Avid Bioservices to Go Private in $1.1B Deal

Dow Jones

2024/11/07

By Connor Hart

Ampersand Capital Partners and GHO Capital Partners said they would take biopharmaceutical company Avid Bioservices private in a $1.1 billion deal.

The Boston- and London-based investment firms, respectively, said Wednesday they would purchase all of Avid's outstanding shares for $12.50 apiece. The purchase price represents a 14% premium to the company's closing price at the end of the regular session, and a 22% premium to its 20-day volume-weighted average share price.

The all-cash deal is expected to close during next year's first quarter, subject to customary closing conditions.

Avid Bioservices Chief Executive Nick Green said the company's board, which unanimously approved the sale, considered several options before determining to move forward as a private company under new owners.

Avid is a contract development and manufacturing organization that provides clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. These services include commercial drug-substance manufacturing, bulk packaging, release and stability testing, and regulatory submissions support.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

November 06, 2024 18:31 ET (23:31 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2481996473"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481996473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2481996473?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 07:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481996473","market":"fut","top_or_hot":-1,"title":"Avid Bioservices to Go Private in $1.1B Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Ampersand Capital Partners and GHO Capital Partners said they would take biopharmaceutical company Avid Bioservices private in a $1.1 billion deal. \n</p>\n<p>\n  The Boston- and London-based investment firms, respectively, said Wednesday they would purchase all of Avid's outstanding shares for $12.50 apiece. The purchase price represents a 14% premium to the company's closing price at the end of the regular session, and a 22% premium to its 20-day volume-weighted average share price. \n</p>\n<p>\n  The all-cash deal is expected to close during next year's first quarter, subject to customary closing conditions. \n</p>\n<p>\n  Avid Bioservices Chief Executive Nick Green said the company's board, which unanimously approved the sale, considered several options before determining to move forward as a private company under new owners. \n</p>\n<p>\n  Avid is a contract development and manufacturing organization that provides clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. These services include commercial drug-substance manufacturing, bulk packaging, release and stability testing, and regulatory submissions support. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 06, 2024 18:31 ET (23:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avid Bioservices to Go Private in $1.1B Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvid Bioservices to Go Private in $1.1B Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-07 07:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Ampersand Capital Partners and GHO Capital Partners said they would take biopharmaceutical company Avid Bioservices private in a $1.1 billion deal. \n</p>\n<p>\n  The Boston- and London-based investment firms, respectively, said Wednesday they would purchase all of Avid's outstanding shares for $12.50 apiece. The purchase price represents a 14% premium to the company's closing price at the end of the regular session, and a 22% premium to its 20-day volume-weighted average share price. \n</p>\n<p>\n  The all-cash deal is expected to close during next year's first quarter, subject to customary closing conditions. \n</p>\n<p>\n  Avid Bioservices Chief Executive Nick Green said the company's board, which unanimously approved the sale, considered several options before determining to move forward as a private company under new owners. \n</p>\n<p>\n  Avid is a contract development and manufacturing organization that provides clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. These services include commercial drug-substance manufacturing, bulk packaging, release and stability testing, and regulatory submissions support. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 06, 2024 18:31 ET (23:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDMOP","symbol_name":"Avid Bioservices, Inc. 10.50% Series E Convertible Preferred","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481996473","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481996473","pubTimestamp":1730935860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Ampersand Capital Partners and GHO Capital Partners said they would take biopharmaceutical company Avid Bioservices private in a $1.1 billion deal.The Boston- and London-based investment firms, respectively, said Wednesday they would purchase all of Avid's outstanding shares for $12.50 apiece. The purchase price represents a 14% premium to the company's closing price at the end of the regular session, and a 22% premium to its 20-day volume-weighted average share price.The all-cash deal is expected to close during next year's first quarter, subject to customary closing conditions.Avid Bioservices Chief Executive Nick Green said the company's board, which unanimously approved the sale, considered several options before determining to move forward as a private company under new owners.Avid is a contract development and manufacturing organization that provides clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. These services include comme","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDMOP":"Avid Bioservices, Inc. 10.50% Series E Convertible Preferred","CDMO":"Avid Bioservices, Inc.","BK4139":"生物科技"},"translate_title":"Avid Bioservices将以$1.1 B交易私有化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMOP":1,"CDMO":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Ampersand Capital Partners and GHO Capital Partners said they would take biopharmaceutical company Avid Bioservices private in a $1.1 billion deal. \n\n\n  The Boston- and London-based investment firms, respectively, said Wednesday they would purchase all of Avid's outstanding shares for $12.50 apiece. The purchase price represents a 14% premium to the company's closing price at the end of the regular session, and a 22% premium to its 20-day volume-weighted average share price. \n\n\n  The all-cash deal is expected to close during next year's first quarter, subject to customary closing conditions. \n\n\n  Avid Bioservices Chief Executive Nick Green said the company's board, which unanimously approved the sale, considered several options before determining to move forward as a private company under new owners. \n\n\n  Avid is a contract development and manufacturing organization that provides clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. These services include commercial drug-substance manufacturing, bulk packaging, release and stability testing, and regulatory submissions support. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2024 18:31 ET (23:31 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}